Increase of E-cigarette Use during Teenage Pregnancy

Industry Insight by 2FIRSTS.ai
Dec.15.2023
Increase of E-cigarette Use during Teenage Pregnancy
Teenage e-cigarette use during pregnancy has risen from 0.8% in 2016 to 4.1% in 2021, according to a study.

According to a study published online on December 13th in JAMA Network Open, the prevalence of e-cigarette use in late pregnancy among adolescents in the United States has increased from 0.8% in 2016 to 4.1% in 2021.

 

Researchers primarily analyzed data from the 2016-2021 Pregnancy Risk Assessment Monitoring System. They specifically focused on 10,428 teenagers aged 10-19 who had previously given birth to a singleton and provided information on their use of e-cigarettes or conventional cigarettes.

 

Although researchers found that the prevalence of exclusive e-cigarette use has increased by approximately five-fold, the percentage of pregnant women who only use conventional cigarettes has decreased from 9.2% in 2017 to 3.2% in 2021. The proportion of pregnant women who use both e-cigarettes and conventional cigarettes fluctuated between 0.6% and 1.6%.

 

There was no significant difference in the proportion of low birth weight among non-smoking or non-e-cigarette using adolescents (12.9%), e-cigarette only users (16.8%), or adolescents who used both cigarettes and e-cigarettes (17.6%). However, researchers found a significant association between smoking only and the proportion of low birth weight (24.6%).

 

In this study, Dr. Xiaozhong Wen, corresponding author from the Jacobs School of Medicine and Biomedical Sciences at the State University of New York, Buffalo, stated:

 

In our analysis, using only e-cigarettes and using both traditional cigarettes and e-cigarettes simultaneously appears to have no significant statistical association with lower birth weight. However, considering the lower prevalence of usage and limited sample size, this finding should be interpreted with caution.

 

The limitations of this study lie in the possibility that participants may underreport their use of e-cigarettes and traditional cigarettes out of concern for social stigma. Additionally, researchers lack information on the use of e-cigarettes during the first and second trimesters of pregnancy, exposure to secondhand smoke, marijuana use, and dietary habits.

 

This study was supported by the National Institute on Drug Abuse, the Center for Tobacco Products of the Food and Drug Administration, the National Heart, Lung, and Blood Institute, as well as the American Heart Association. One of the co-authors of the study has received grants from Pfizer Inc. and personal fees from Johnson & Johnson, the World Health Organization, and the Campaign for Tobacco-Free Kids.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | 30ml E-Liquid, 40,000 Puffs, and Three Power Settings: OXBAR Launches New DTL Product ROVOTA
Product | 30ml E-Liquid, 40,000 Puffs, and Three Power Settings: OXBAR Launches New DTL Product ROVOTA
E-cigarette brand OXBAR has launched its new DTL e-cigarette, the OXBAR ROVOTA, on its official website. The product contains 30ml of e-liquid and is officially rated for up to approximately 40,000 puffs. It has a nicotine strength of 6mg and offers around 15 flavor options. The device is equipped with a 1400mAh battery, supports Type-C charging, features a 0.4Ω dual mesh coil, and supports three power settings of 20W, 30W, and 40W.
Mar.31 by 2FIRSTS.ai
Report says illegal vapes “threaten UK high streets” as 55% of councils seized thousands last year
Report says illegal vapes “threaten UK high streets” as 55% of councils seized thousands last year
The latest annual Illegal Vapes and Nicotine Product Report says nearly 5 million illegal vapes have been seized over the last three years—equivalent to three seized every minute—with a street value of £39m (USD equivalent not provided in the source; exchange-rate basis not stated). It says 1.3 million were seized last year and that 55% of UK council areas seized thousands of illegal products over the year.
Feb.26 by 2FIRSTS.ai
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
British American Tobacco is facing a shareholder lawsuit in London alleging it failed to properly disclose to markets information about breaches of U.S. sanctions linked to its North Korea-related business. BAT agreed in 2023 to pay more than $635 million to U.S. authorities after a subsidiary admitted conspiring to violate U.S. sanctions by selling tobacco products to North Korea and committing bank fraud from 2007 to 2017.
Mar.05 by 2FIRSTS.ai
Austria to Tighten Sales Rules for Nicotine Pouches and E-Liquids From April 1
Austria to Tighten Sales Rules for Nicotine Pouches and E-Liquids From April 1
Austria will introduce new sales rules for nicotine products from April 1, 2026. Under a reform of the tobacco law passed in December 2025, nicotine pouches will in future be sold only through tobacco shops, while e-liquids will be sold only through tobacco shops and licensed specialist stores. Other points of sale will no longer be permitted to sell these products.
Mar.30 by 2FIRSTS.ai
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Alexander Tolmachev, deputy chairman of the Russian State Duma Committee on Youth Policy, said the issue of licensing vape circulation will be resolved at the legislative level in the coming months. He said a significant share of such products currently on the market are counterfeit, that their real nicotine concentration may be several times higher than stated, and that the composition of the liquid is unknown.
Mar.18 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11